Skip to main content

Advertisement

SpringerLink
Log in

CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG ODN) act as potent Th1-like immune enhancers with many antigens in animal models. We have extended these observations to the first clinical evaluation of the safety, tolerability and immunogenicity of CPG 7909 when added to a commercial HBV vaccine. In a randomized, double-blind phase I dose escalation study, healthy volunteers aged 18–35 years were vaccinated at 0, 4 and 24 weeks by intramuscular injection with Engerix-B® (GlaxoSmithKline). The regular adult dose of 20 μg recombinant hepatitis B surface antigen (HBsAg) adsorbed to alum was administered mixed with saline (control) or with CPG 7909 at one of three doses (0.125, 0.5 or 1.0 mg). HBsAg-specific antibody responses (anti-HBs) appeared significantly sooner and were significantly higher at all timepoints up to and including 24 weeks in CPG 7909 recipients compared to control subjects (p⩽0.001). Strikingly, most CpG 7909-vaccinated subjects developed protective levels of anti-HBs IgG within just two weeks of the priming vaccine dose. A trend towards higher rates of positive cytotoxic T cell lymphocyte responses was noted in the two higher dose groups of CPG 7909 compared to controls. The most frequently reported adverse events were injection site reactions, flu-like symptoms and headache. While these were more frequent in CPG 7909 groups than in the control group (p<0.0001), most were reported to be of mild to moderate intensity regardless of group. In summary, CPG 7909 as an adjuvant to Engerix-B was well-tolerated and enhanced vaccine immunogenicity. CPG 7909 may allow the development of a two-dose prophylactic HBV vaccine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee WM: Hepatitis B virus infection. N Engl J Med337:1733–1745, 1997

    Google Scholar 

  2. Maddrey WC: Hepatitis B: An important public health issue. J Med Virol61:362–366, 2000

    Google Scholar 

  3. Hepatitis B Vaccination–United States, 1982–2002, MMWR Morb Mortal Wkly Rep51:549–552, 563, 2002

    Google Scholar 

  4. Chisari FV: Cytotoxic T cells and viral hepatitis. J Clin Invest99:1472–1477, 1997

    Google Scholar 

  5. Rehermann B: Intrahepatic T cells in hepatitis B: Viral control versus liver cell injury. J Exp Med191:1263–1268, 2000

    Google Scholar 

  6. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol20:709–760, 2002

    Google Scholar 

  7. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med186:1623–1631, 1997

    Google Scholar 

  8. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K: CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol27:2340–2344, 1997

    Google Scholar 

  9. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med3:849–854, 1997

    Google Scholar 

  10. Krieg AM, Davis HL: Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther3:15–24, 2001

    Google Scholar 

  11. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol34:251–262, 2004

    Google Scholar 

  12. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, Weeranta R: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol160:870–876, 1998

    Google Scholar 

  13. Weeratna R, Comanita L, Davis HL: CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALBc mice. Immunol Cell Biol81:59–62, 2003

    Google Scholar 

  14. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist CA, Davis HL: Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol30:241–247, 2001

    Google Scholar 

  15. Weeratna RD, McCluskie MJ, Xu Y, Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine18:1755–1762, 2000

    Google Scholar 

  16. McCluskie MJ, Davis HL: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol161:4463–4466, 1998

    Google Scholar 

  17. Davis HL, Suparto II, Weeratna RR, Jumintarto Iskandriati DD, Chamzah SS, Ma’ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto Smits W, Sajuthi DD: CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine18:1920–1924, 2000

    Google Scholar 

  18. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol164:1617–1624, 2000

    Google Scholar 

  19. Halperin SA, van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ: A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine21:2461–2467, 2003

    Google Scholar 

  20. Ambrosch F, Wiedermann G, Kundi M, Leroux-Roels G, Desombere I, Garcon N, Thiriart C, Slaoui M, Thoelen S: A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 18:2095–2101, 2000

    Google Scholar 

  21. Thoelen S, van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, Vandepapeliere P, Slaoui M, Meheus A: Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine16:708–714, 1998

    Google Scholar 

  22. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4:201–206, 1994

    Google Scholar 

  23. West DJ: Clinical experience with hepatitis B vaccines. Am J Infect Control17:172–180, 1989

    Google Scholar 

  24. Hasan MS, Agosti JM, Reynolds KK, Tanzman E, Treanor JJ, Evans TG: Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J Infect Dis 180:2023–2026, 1999

    Google Scholar 

  25. Evans TG, Hasan M, Galibert L, Caron D: The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults. Vaccine21:322–329, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Ottawa at The Ottawa Hospital and Ottawa Health Research Institute, Ottawa, Canada

    C.L. COOPER & D.W. CAMERON

  2. Coley Pharmaceutical Group, Ottawa, Canada and Wellesley, Massachusetts

    H.L. DAVIS, M.L. MORRIS & S.M. EFLER

  3. Pharmaceutical Group, Wellesley, Massachusetts

    M. AL ADHAMI & A.M. KRIEG

  4. Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Canada

    J. HEATHCOTE

Authors
  1. C.L. COOPER
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.L. DAVIS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M.L. MORRIS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S.M. EFLER
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. AL ADHAMI
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A.M. KRIEG
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D.W. CAMERON
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. HEATHCOTE
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C.L. COOPER.

Rights and permissions

Reprints and permissions

About this article

Cite this article

COOPER, C., DAVIS, H., MORRIS, M. et al. CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study. J Clin Immunol 24, 693–701 (2004). https://doi.org/10.1007/s10875-004-6244-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-004-6244-3

Search

Navigation